Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


IL-8 and cancer prognosis on immunotherapy

Interleukin-8, produced by intratumoral and circulating myeloid cells, correlates with an immunosuppressive myeloid-enriched tumor microenvironment and adverse cancer prognosis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Production of IL-8 and effects on circulating immune cells, the tumor microenvironment and patient prognosis.


  1. Ha, H., Debnath, B. & Neamati, N. Theranostics 7, 1543–1588 (2017).

    Article  CAS  Google Scholar 

  2. Alfaro, C. et al. Cancer Treat. Rev. 60, 24–31 (2017).

    Article  CAS  Google Scholar 

  3. Sanmamed, M. F. et al. Ann. Oncol. 28, 1988–1995 (2017).

    Article  CAS  Google Scholar 

  4. Schalper, K.A. et al. Nat. Med. (2020).

  5. Yuen, K.C. et al. Nat. Med. (2020).

  6. McDermott, D. F. et al. Nat. Med. 24, 749–757 (2018).

    Article  CAS  Google Scholar 

  7. Mariathasan, S. et al. Nature 554, 544–548 (2018).

    Article  CAS  Google Scholar 

  8. DeNardo, D. G. & Ruffell, B. Nat. Rev. Immunol. 19, 369–382 (2019).

    Article  CAS  Google Scholar 

  9. Freidlin, B. & Korn, E. L. Nat. Rev. Clin. Oncol. 11, 81–90 (2014).

    Article  Google Scholar 

  10. Hayes, D. F. Mol. Oncol. 9, 960–966 (2015).

    Article  Google Scholar 

  11. Bilusic, M. et al. J. Immunother. Cancer 7, 1–8 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Toni K. Choueiri.

Ethics declarations

Competing interests

Z.B. receives research support from Bristol-Myers Squibb and Genentech/imCore. T.C. receives research support from and consults for Roche, Bristol-Myers Squibb, Exelixis, Merck, Pfizer, EMD Serono and AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bakouny, Z., Choueiri, T.K. IL-8 and cancer prognosis on immunotherapy. Nat Med 26, 650–651 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer